ALPS Group Inc Dossier
Qualitative Analysis
Business overview
Alps Group Inc (NASDAQ: ALPS) is a Malaysia-based integrated biotechnology research and healthcare platform headquartered in Kuala Lumpur. Operating as the parent company of Alps Life Sciences Inc. (Alps Holdco), the company specializes in predictive, preventive, and precision medicine. Its comprehensive ecosystem integrates research and development, medical services, and wellness solutions. Key offerings include DNA and mRNA sequencing, cellular therapies (such as NK and CAR-T cells), mRNA vaccines, and stem cell technologies. The company operates a GMP cell manufacturing lab, a molecular diagnostics lab, a medical center, and a wellness center, creating a seamless bench-to-bedside continuum.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding the clinical and research adoption of Whole Genome Sequencing (WGS) through its subsidiary, MyGenome Sdn. Bhd., following its MS ISO 15189:2022 accreditation.
Expected impact: Broadens Alps' addressable market to include government-linked healthcare programs, cross-border partnerships, and institutional clients across Southeast Asia.
Potential expansion of the company's exosome-related pipeline beyond its previously disclosed CELESOME(+) program, following the publication of a clinical case series on nebulized human umbilical cord mesenchymal stem cell (hUCMSC) derived exosomes.
Expected impact: Aims to address significant unmet medical needs in pulmonary diseases such as asthma and chronic obstructive pulmonary disease (COPD).
Advancing its autologous Natural Killer (NK) cell pipeline using an in-house developed culture protocol (patent application PI2025002484) that enables cost-effective, large-scale production of highly pure NK cells.
Expected impact: Lowers manufacturing barriers and improves the safety profile of NK cells, positioning the company for future clinical investigations in broader patient populations.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Completed a business combination (reverse merger) with special purpose acquisition company Globalink Investment Inc., enabling Alps Global Holding Berhad to transition into the publicly traded entity Alps Group Inc on the Nasdaq Stock Market.
Financial impact: Resulted in the combined company trading on Nasdaq under the ticker symbol 'ALPS' with an estimated enterprise value of approximately $1.6 billion at closing.